Most recent by Rebecca L. Forand
Yuflyma becomes fourth Humira biosimilar to receive interchangeability status
The FDA has accepted Yuflyma as an interchangeable biosimilar to adalimumab for the treatment of multiple chronic inflammatory diseases, Celltrion USA announced in a press release.
Journey’s oral minocycline product Emrosi significantly improves rosacea
Patients with rosacea experienced improvement with Emrosi, an oral minocycline hydrochloride extended-release product, according to results from two phase 3 clinical trials.
Transmasculine patients with acne need specialized care
ORLANDO — Treating acne in transmasculine patients requires sensitivity to unique challenges, according to a speaker at the American Academy of Dermatology annual meeting.
Diversity remains paramount in research from basic to clinical stages
ORLANDO — Increasing diversity in research, from basic and translational to clinical science, is more important than ever and clinicians need to meet people where they are to do so, according to a panel discussion here.
Laser options abound for treating burn, trauma scars
ORLANDO — Innovations in treating burn and trauma scars in recent years include updated laser technology, giving practitioners options to help in these difficult cases, according to a speaker here.
Itch poses ‘major challenge’ in aging adults, but must be addressed
ORLANDO — Itching in older patients should not be dismissed as simply dry skin, but rather approached as a complex problem involving numerous causes, according to a speaker at the American Academy of Dermatology Annual Meeting.
Desai: Path to successful leadership paved with servitude, introspection, authenticity
ORLANDO — Seemal R. Desai, MD, FAAD, who is finishing his term as American Academy of Dermatology president, took time to reflect on his own leadership journey and inspire future leaders at the Skin of Color Society Scientific Symposium.
Dermatologists must be ‘actively involved’ in AI development to reduce disparities
ORLANDO — AI can transform how dermatologists diagnose skin conditions including melanoma; however, without attention to equitability, specifically in skin of color, it could exacerbate disparities in care, according to a speaker here.
Tildrakizumab shows long-term scalp psoriasis improvement
Scalp psoriasis improvement was maintained with long-term tildrakizumab treatment in what researchers said is the first “dedicated trial” to demonstrate sustainable efficacy of an anti-interleukin-23 inhibitor for the condition.
FDA approves two hyaluronic acid fillers for nasolabial folds
The FDA has approved Evolysse Form and Evolysse Smooth injectable hyaluronic acid gels, two dermal fillers from Evolus, the company announced in a press release.